The retrospective cost analysis estimates direct in-patient costs and length of stay (LOS) in hospital for acute heart failure (AHF).
Introduction
Chronic heart failure (CHF) is a complex syndrome with poor prognosis, which is defined as a combination of following signs and symptoms: breathlessness and fatigue at rest or during exertion; ankle swelling; and, objective evidence of cardiac dysfunction at rest and clinical response to treatment towards heart failure [1] . The prevalence of symptomatic heart failure is estimated to range from 0.4% to 2% in the general European population. Heart failure occurs in approximately 10% of patients older than 65 years, and CHF is one of the most common causes of hospitalization [2] . The incidence of heart failure has declined among women but not men, whereas survival has improved among both sexes over the past 50 years. Generally, the mortality of diseases of circulatory system dropped by 20% between 1996 and 2005 (European health for all database, WHO). As CHF progresses, most patients require increasingly frequent hospitalization to manage the acute decompensation of heart failure. The prognosis of heart failure is comparable with that of the worst malignant diseases [3] .
Acute heart failure (AHF) is seen as aggravation of chronic heart failure (acute decompensation), but is still often perceived as a detached disease; new onset of AHF (de-novo AHF) in patients without previously known cardiac dysfunction. AHF is defined as the rapid onset of symptoms and signs secondary to abnormal cardiac function. The cardiac dysfunction can be related to systolic or diastolic dysfunction, to abnormalities in cardiac rhythm, or to preload and afterload mismatch. The clinical presentation of acute heart failure ranges from sudden appearances of dyspnoea to frank cardiogenic shock. AHF is life threatening disease which includes variable causes and complications. The major therapeutic aim is to control symptoms and to stabilize the haemodynamic condition. The prognosis of patients improves by immediate elimination of inciting cause of the acute state (ischaemia by surgical or interventional revascularization, valvular disease by operation, arrhythmias by antiarrhythmic drugs or defibrillation etc.) or applying appropriate pharmacotherapy and preventive precautions to prevent from progression of the disease with future acute decompensation [4] .
The mainstay of diagnosis is clinical examination, complemented with x-ray, electrocardiography, echocardiography or another imaging technique, and biochemistry, with determination of natriuretic peptides being the most valuable diagnostic tool. The first European guidelines for the diagnosis and treatment of acute heart failure dates back to 2005 [1] , followed by the Czech guidelines a year later [5] . These guidelines provide a more accurate classification of acute heart failure into six categories while also highlighting the fact that a major proportion (up to 50%) of cases of acute heart failure is not associated with systolic left ventricular dysfunction [6] . Acute heart failure difficult to treat and is a condition associated with high mortality rates. Since no large mortality studies demonstrating an effect of treatment on survival have been reported, treatment is based on experience and is largely empirical. Factors central to the decision regarding the therapy to be used include the patient's clinical condition and the cause of heart failure. The main class of drugs used in pharmacotherapy are diuretics, with vasodilators used in patients with a hypertensive response while, conversely, positive inotropic agents are administered to those with hypotension. All these modes of action are combined in levosimendan, a calcium sensitizer. Drug therapy is usually complemented with mechanical ventilation, and/or methods of elimination. Some patients require surgery, and various support systems have emerged recently, which hold promise for the most critically ill [7] .
Material and Methods
The purpose of the retrospective cost analysis was to estimate the in-hospital costs and length of stay in acute heart failure patients hospitalized in the Faculty Hospital The database is currently in electronic format, and upgraded for on-line collection and evaluation of the data acquired. The format of data provides information about the aetiology, treatment, and prognosis of patients hospitalized for acute heart failure [8] . The inclusion criterion to the costing part of AHEAD study was that the patients were admitted due to the decompensation or new onset of acute heart failure to the Department of Internal Cardiology FH Brno in 2005 and 2006. This centre is specialized for treatment of patients with acute coronary syndromes; its catchment area includes 500,000 potential cardiac patients. The general internal medicine area covers only 20,000 people to be treated in one centre. The department is one of the prominent centres in the Czech Republic in regards to the care of patients with acute coronary syndromes and acute heart failure. It is fully equipped with the latest technical devices to provide advance medical treatment, to shorten the necessary hospitalization stay and prevent the development of chronic heart failure. Such devices and methods are very expensive. Presently the reperfusion therapy in acute myocardial infarction patients is being performed by means of PCI (percutaneous coronary intervention) with stent implantations either as an emergency procedure immediately following entry or as an elective intervention later during hospitalization in a stabilized patient. Because of the fact that non-acute interventions are often performed during the same and not another (elective) hospitalization the characteristics of patients and associated costs of their hospitalizations at the cardiologic department FH Brno may be slightly different when compared to a "standard" patient in the Czech Republic. The cardiologic department admits patients that have been hospitalized with new onset AHF symptoms of acute coronary ischaemic or nonischaemic aetiology as well as patients with acute decompensation of heart failure.
The analysis was undertaken from a health care payer's perspective; neither the indirect (e.g., loss of earnings) nor the intangible costs (e.g., pain, suffering) were measured. The costs were extracted from the hospital cost of each registered patient. The burden incurred during the first hospitalization is divided to burden of standard cardiology unit (SCU) and burden of intensive care unit (ICU). In-patient care costs include flat rate of admission and stay, rates of investigations and interventions undergone. The pharmaceuticals used during the stay in hospital are included in the daily in-patient rate, the extra medications and extra sanitary materials used during medical procedures are calculated separately. The costs of daily care in the ICU are counted according to TISS scores (Therapeutic Intervention Scoring System). All charges come from fixed fee schedules in the index of medical procedures (physicians´ services) and the code- [9] . The aim is to evaluate the cost of first during the study hospitalization in new onset of AHF (patients without previously known cardiac dysfunction) as well as in the group of acute decompensation of heart failure patients. Subsequent hospitalizations were not yet evaluated because the prospective data collection still continues and needs enough follow-up to be interpreted correctly.
Results
In total, 734 patients (57% male) with acute heart failure were analysed. The mean age was 71.7 years (minimum 21 years, maximum 98 years); 81.5% were more than 60 years old and 61% were more than 70 years old. Acute decompensation of chronic heart failure was found in 41.4% of patients, others were diagnosed as new onset of AHF without previously known cardiac dysfunction. Figure 1 summarizes the aetiology of acute heart failure. The patients' history revealed that most patients suffered from hypertension (65.7%), diabetes mellitus (38.1%), angina (34.1%), cerebrovascular disease (stroke and transient ischaemic attack) and renal insufficiency (both less than 20%). Before hospitalization, 32.4% of the study patients had myocardial infarction, 8% had undergone percutaneous coronary intervention (PCI) and 3.3% coronary artery bypass graft (CABG). Pacemakers were present in 8.3% and implantable cardioverter-defibrillators (ICD) in 1.8% of all patients. The baseline characteristic of patients on admission is summarized in Table 1 .
The overall direct hospital cost of all patients was €2.4 million. The mean hospital stay was 8.3 days and mean in-patient cost was €3295 (including all interventions). Almost a half of all passed through both standard cardiology unit (SCU) and intensive care unit (ICU); 30% SCU only and 23% ICU only. The mean length of stay in the SCU was 8.3 days with one-day cost of €55 and the total in-patient cost of €416. The mean length of stay in the ICU was 3.4 days with one- Figure 1 . Aetiology of acute heart failure.
ACS -acute coronary syndrome; STE -ST-segment elevation; CIHDchronic ischaemic heart disease
day cost of €618 and the total in-patient cost of €1762 ( Table 2 ). The total cost of cardiac catheterizations and revascularization procedures which underwent a half (49.9%) of patients was almost a million (€952247). The mean price of the selective coronary angiography was €449 and PCI €3966. Altogether, 38 patients (5%) were sent to the surgery unit to undergo CABG. These costs were not measured by reason of unavailability. The burden of antiarrhythmic interventions (in particular the cost of antiarrhythmic devices) which were fulfilled by 51 patients (6.9%) was €529216 ( Table 3 ). The most expensive factors were revascularization procedures and cardiac catheterizations, which contributed to total in-patient costs by 39%, the stay in the ICU (31%) and the antiarrhythmic interventions (22%) (Figure 2) . The extended cost analysis in accordance with AHF classification approved the new onset of AHF to be more expensive than the acute decompensation of heart failure (median €2803 vs. €889). The difference between costs of new onset of AHF and acute decompensation of heart failure (ADHF) is statistically highly significant (p < 0.001; Mann-Whitney non-parametric test). The most expensive patients were those with clinical characteristics of cardiogenic shock (median €3631). The detailed cost analysis by clinical characteristics is summarized in Table 4 .
The in-hospital mortality associated with heart failure was 14.6%. Most patients were discharged home (65%) and less than 20% were transferred to the other hospital or non-cardiologic unit due to comorbidities. AHF -acute heart failure; ADHF -acute decompensation of heart failure; SD -standard deviation
Discussion
In our study, we evaluated 734 hospitalizations of patients with acute heart failure. The average length of stay was 8.3 days and average hospitalization cost was €3295 which is a very low spending when compared to cost studies from abroad. In the prospect of managed care in the USA, the average length of stay was found to be 7.8 days and the cost of a heart failure hospitalization was USD6433 on average (€6036; 1€ = 1,0658USD) [10, 11] . Moreover, in the retrospective analysis of costs in patients hospitalized for acute decompensated heart failure who were enrolled in REVIVE II study (The Randomized Evaluation of Intravenous Levosimendan Efficacy) the average stay in the hospital network in the USA lasted for 8.96 days with the average cost of USD19021 with standard therapy provided (€13879; 1€ = 1.3705USD) [11, 12] . The cost analysis of SURVIVE (Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support) estimated and compared direct medical costs in patients treated with levosimendan (levo) versus those treated with dobutamine (dob). Cost of hospital admission was calculated as a function of main treatment interventions and length of stay. Source of cost data was standard national hospital payment schedules for France, Germany and United Kingdom. For the index hospital admission, overall length of stay was almost identical across the two study groups, levo 14.3 days and dob 14.5 days (p= 0.98). Days in the intensive care unit (ICU) were also similar (levo 4.6 days, dob 4.5 days; p= 0.27). Cost for the index hospital admission, without including the cost for study drug, was comparable in the levo and dob groups (mean €5060 vs. €4952; p=0.94) [13] . We suppose that this study did not include the costs of antiarrhythmic interventions, including the revascularization procedures which made up 60% of total costs in our study.
Compared to other studies we observed the most difference in the type of heart failure and number of PCI performed. From total 3580 patients, 42% were diagnosed as new onset of AHF in the Euro Heart Failure Survey II (EHFS II) and 49% of 620 patients in the Finnish Acute Heart Failure Study (FINN-AKVA) were new onset AHF patients in comparison with 58.6% in our study [14, 15] . The figure of 30.1% of patients who underwent PCI confirmed that FH Brno is specialized centre for patients with acute coronary syndromes, which were assigned as aetiology of AHF by more than 40% patients in our study. The reperfusion therapy with stenting was carried out at admission or during the course of the stay and significantly increased the costs. The criterion of acute state was the length of stay (LOS) at intensive care unit or coronary care unit. Our results revealed the necessity of intensive care by 70% patients which is higher than others, but the median of LOS was identical. The in-hospital mortality was Table 5 .
We expect another increase of manifestations of acute or chronic heart failure due to aging of the population and much improved care of patients with coronary syndromes. Between 1995-2005 there was a significant decrease in mortality of myocardial infarction by 65% [16] , and within the last 2 years we have noticed another 10% decrease (in the year 2006, 3820 men and 3051 women died of myocardial infarction compared to the year 2005 when 4150 men and 3202 women died) [17, 18] . The mortality rate due to AHF is usually an underestimate because guidance on death certificates discourages citation of heart failure as the cause of death, preferring physicians to code the underlying aetiology (e.g., coronary artery disease) [19] .
The treatment of heart failure patients uses 1 -2% of health care budget in developed European countries of which 2/3 are being spent on hospitalizations [20] . In the Czech Republic in 2006, diseases of the circulatory system made up 15% of all hospitalizations (345732 in total) with the average 9.6 in-patient days. The total expenses of health insurance companies rise every year. The present hospital costs make up 44.4% of all expenditures of the health care service and for this reason it is one of the most finance-consuming items. The cardiovascular system drugs formed 17.7% of all distributed medicaments in 2006, with the total sum of CZK 10.37 billion (1€ = 29CZK) [9, 18] .
The knowledge of expenses on the therapy of acute cardiovascular events is a very important factor to create the pharmacoeconomic models of preventive projects that include future expenditures on the therapy of acute events that develop most often as a consequence of civilization diseases or as a complication of other diseases. The investments in prevention are then to be interpreted as financially effective in comparison to the up-coming treatment of costly diseases. The cost comparative data are the basis of the complex pharmacoeconomic studies, such as models, costeffectiveness or cost-utility studies, which demand the knowledge of various individual clinical syndromes and are necessary when requesting reimbursement for newly registered remedies. The information about real expenses that health institutions spend on each patient with a diagnosis in view as well as on each intervention performed is very important when making a decision about the reimbursement of the most expensive therapeutic procedures. Such decisions are usually made on the basis of willingness-to-pay, i.e., a defined maximum cost for QALY (quality-adjusted-life-years).
Study limitation
The generalization of results is not possible without emphasising our study population. As mentioned above, the Faculty Hospital Brno has a large catchment area and its patients might be more severely ill than the patients treated in smaller local hospitals. We are one of the research active centres that provides advanced medical treatments. When comparing the cost results with foreign studies without knowing the background of these centres, the confrontation is only approximate, e.g., different health services treat patients with the same diagnosis in different ways. Our primary endpoint was to carry out a detailed analysis in patients hospitalized for acute heart failure (e.g., the severity of disease, the clinical characteristics of patients, the costs associated with AHF hospitalization) in conditions of renowned cardiologic centre in the Czech Republic. There are several methods to compare the charges between countries. We decided to use the annual mean exchange rates to make it easier to understand for readers. On the other hand there are some economic methods available to currency conversion based on purchasing power parity which reflect differences in price levels between countries and might be more suitable for economic experts. However, we do not expect the usage of our results in outland studies because the transferability of cost studies is not recommended by authorities [21] .
Conclusions
Acute heart failure hospitalization is a significant source of health care expenditures and has become more frequent as the population ages and medical care improves survival after acute coronary syndromes (ACS). ACS (with/without STE) was the most common cause of hospitalization with high costs of revascularization procedures.
The overall direct hospital cost of all patients within first hospitalization was €2.4 million, length of hospital admission was 8.3 days, and mean inpatient cost was €3295 (including all interventions). The predominant contributors of high in-patient costs are revascularization procedures (39% of total costs), admission in the intensive care unit (31% of total costs) and antiarrhythmic interventions (22% of total costs). The hospital costs in patients with new onset of acute heart failure were significantly higher than in patients with acute decompensation of chronic heart failure (median €2803 vs. €889).
Acute heart failure is associated with poor prognosis; the in-hospital mortality was 14.6%. Due to the ever-rising morbidity of patients with heart failure and associated increases in hospitalization, mortality and costs, there is an obvious need to inform medical specialists, hospital management and health insurance companies about the costs of management of AHF.
It will be interesting and instructive to monitor patients after their discharge from the hospital and to evaluate costs of their upcoming re-hospitalizations because of the fact that 45% of patients with AHF are being readmitted into hospitals within one year [3] .
